nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludrocortisone—Aseptic necrosis—Methotrexate—bone cancer	0.0458	0.0698	CcSEcCtD
Fludrocortisone—Glucose tolerance impaired—Cisplatin—bone cancer	0.0357	0.0544	CcSEcCtD
Fludrocortisone—Papilloedema—Cisplatin—bone cancer	0.0303	0.0461	CcSEcCtD
Fludrocortisone—NR3C2—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0227	0.0768	CbGpPWpGaD
Fludrocortisone—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.0226	0.0766	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.0185	0.0625	CbGpPWpGaD
Fludrocortisone—Diabetic—Methotrexate—bone cancer	0.0158	0.0241	CcSEcCtD
Fludrocortisone—Optic neuritis—Cisplatin—bone cancer	0.0157	0.0238	CcSEcCtD
Fludrocortisone—Osteonecrosis—Methotrexate—bone cancer	0.0142	0.0216	CcSEcCtD
Fludrocortisone—Cardiomegaly—Epirubicin—bone cancer	0.0135	0.0206	CcSEcCtD
Fludrocortisone—AR—Nuclear Receptors—NR1I2—bone cancer	0.0133	0.0451	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.0127	0.043	CbGpPWpGaD
Fludrocortisone—Cardiomegaly—Doxorubicin—bone cancer	0.0125	0.0191	CcSEcCtD
Fludrocortisone—Impaired healing—Methotrexate—bone cancer	0.0122	0.0186	CcSEcCtD
Fludrocortisone—Infection—Carboplatin—bone cancer	0.0116	0.0177	CcSEcCtD
Fludrocortisone—NR3C2—Generic Transcription Pathway—ZNF77—bone cancer	0.0116	0.0392	CbGpPWpGaD
Fludrocortisone—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.0107	0.0362	CbGpPWpGaD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.0105	0.0357	CbGpPWpGaD
Fludrocortisone—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0105	0.0356	CbGpPWpGaD
Fludrocortisone—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.0101	0.0342	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00965	0.0327	CbGpPWpGaD
Fludrocortisone—Osteoporosis—Methotrexate—bone cancer	0.00942	0.0143	CcSEcCtD
Fludrocortisone—Hypernatraemia—Epirubicin—bone cancer	0.0094	0.0143	CcSEcCtD
Fludrocortisone—Fluid retention—Cisplatin—bone cancer	0.00914	0.0139	CcSEcCtD
Fludrocortisone—Fracture—Methotrexate—bone cancer	0.00909	0.0138	CcSEcCtD
Fludrocortisone—Multiple fractures—Methotrexate—bone cancer	0.00909	0.0138	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Methotrexate—bone cancer	0.00888	0.0135	CcSEcCtD
Fludrocortisone—Hypernatraemia—Doxorubicin—bone cancer	0.0087	0.0132	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Epirubicin—bone cancer	0.00831	0.0127	CcSEcCtD
Fludrocortisone—Optic neuritis—Epirubicin—bone cancer	0.00804	0.0122	CcSEcCtD
Fludrocortisone—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00799	0.027	CbGpPWpGaD
Fludrocortisone—Cardiac failure congestive—Cisplatin—bone cancer	0.00771	0.0117	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Doxorubicin—bone cancer	0.00769	0.0117	CcSEcCtD
Fludrocortisone—Optic neuritis—Doxorubicin—bone cancer	0.00744	0.0113	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Cisplatin—bone cancer	0.00722	0.011	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Epirubicin—bone cancer	0.00668	0.0102	CcSEcCtD
Fludrocortisone—Petechiae—Methotrexate—bone cancer	0.00642	0.00978	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Doxorubicin—bone cancer	0.00618	0.00941	CcSEcCtD
Fludrocortisone—Glycosuria—Epirubicin—bone cancer	0.0061	0.00929	CcSEcCtD
Fludrocortisone—Petechiae—Epirubicin—bone cancer	0.00601	0.00915	CcSEcCtD
Fludrocortisone—Pancreatitis—Cisplatin—bone cancer	0.00592	0.00902	CcSEcCtD
Fludrocortisone—Sweating increased—Cisplatin—bone cancer	0.00588	0.00896	CcSEcCtD
Fludrocortisone—Glycosuria—Doxorubicin—bone cancer	0.00565	0.0086	CcSEcCtD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.00564	0.0191	CbGpPWpGaD
Fludrocortisone—Amenorrhoea—Epirubicin—bone cancer	0.00563	0.00857	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—ZNF77—bone cancer	0.00558	0.0189	CbGpPWpGaD
Fludrocortisone—Petechiae—Doxorubicin—bone cancer	0.00556	0.00847	CcSEcCtD
Fludrocortisone—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.00537	0.0182	CbGpPWpGaD
Fludrocortisone—Amenorrhoea—Doxorubicin—bone cancer	0.00521	0.00793	CcSEcCtD
Fludrocortisone—Ecchymosis—Methotrexate—bone cancer	0.00478	0.00727	CcSEcCtD
Fludrocortisone—Neoplasm—Methotrexate—bone cancer	0.00478	0.00727	CcSEcCtD
Fludrocortisone—Fluid retention—Epirubicin—bone cancer	0.00469	0.00715	CcSEcCtD
Fludrocortisone—Hydrocortamate—CYP3A4—bone cancer	0.00465	0.0974	CrCbGaD
Fludrocortisone—Cortisone acetate—CYP3A4—bone cancer	0.00458	0.0959	CrCbGaD
Fludrocortisone—Oesophagitis—Epirubicin—bone cancer	0.00452	0.00688	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Epirubicin—bone cancer	0.00449	0.00684	CcSEcCtD
Fludrocortisone—Ecchymosis—Epirubicin—bone cancer	0.00447	0.00681	CcSEcCtD
Fludrocortisone—Neoplasm—Epirubicin—bone cancer	0.00447	0.00681	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Methotrexate—bone cancer	0.00443	0.00674	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Methotrexate—bone cancer	0.00441	0.00671	CcSEcCtD
Fludrocortisone—Fluid retention—Doxorubicin—bone cancer	0.00434	0.00661	CcSEcCtD
Fludrocortisone—Erythema—Cisplatin—bone cancer	0.00421	0.00641	CcSEcCtD
Fludrocortisone—Oesophagitis—Doxorubicin—bone cancer	0.00418	0.00636	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Doxorubicin—bone cancer	0.00416	0.00633	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Epirubicin—bone cancer	0.00415	0.00631	CcSEcCtD
Fludrocortisone—Neoplasm—Doxorubicin—bone cancer	0.00414	0.0063	CcSEcCtD
Fludrocortisone—Ecchymosis—Doxorubicin—bone cancer	0.00414	0.0063	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Epirubicin—bone cancer	0.00413	0.00628	CcSEcCtD
Fludrocortisone—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.00408	0.0138	CbGpPWpGaD
Fludrocortisone—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.00407	0.0138	CbGpPWpGaD
Fludrocortisone—Eplerenone—CYP3A4—bone cancer	0.00402	0.0842	CrCbGaD
Fludrocortisone—Vascular purpura—Epirubicin—bone cancer	0.00401	0.00611	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Methotrexate—bone cancer	0.00396	0.00603	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Epirubicin—bone cancer	0.00396	0.00602	CcSEcCtD
Fludrocortisone—NR3C2—Generic Transcription Pathway—NR1I2—bone cancer	0.00392	0.0133	CbGpPWpGaD
Fludrocortisone—Thrombophlebitis—Doxorubicin—bone cancer	0.00384	0.00584	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Doxorubicin—bone cancer	0.00382	0.00581	CcSEcCtD
Fludrocortisone—Purpura—Epirubicin—bone cancer	0.00372	0.00567	CcSEcCtD
Fludrocortisone—Vascular purpura—Doxorubicin—bone cancer	0.00371	0.00565	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Epirubicin—bone cancer	0.00371	0.00565	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Doxorubicin—bone cancer	0.00366	0.00557	CcSEcCtD
Fludrocortisone—Convulsion—Cisplatin—bone cancer	0.00365	0.00555	CcSEcCtD
Fludrocortisone—Mood swings—Methotrexate—bone cancer	0.00363	0.00553	CcSEcCtD
Fludrocortisone—Myalgia—Cisplatin—bone cancer	0.00358	0.00546	CcSEcCtD
Fludrocortisone—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.00354	0.012	CbGpPWpGaD
Fludrocortisone—Affect lability—Epirubicin—bone cancer	0.00353	0.00538	CcSEcCtD
Fludrocortisone—Fluorometholone—CYP3A4—bone cancer	0.0035	0.0732	CrCbGaD
Fludrocortisone—Purpura—Doxorubicin—bone cancer	0.00345	0.00525	CcSEcCtD
Fludrocortisone—Oedema—Cisplatin—bone cancer	0.00343	0.00523	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Cisplatin—bone cancer	0.00343	0.00523	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00343	0.00522	CcSEcCtD
Fludrocortisone—Infection—Cisplatin—bone cancer	0.00341	0.0052	CcSEcCtD
Fludrocortisone—Mood swings—Epirubicin—bone cancer	0.0034	0.00518	CcSEcCtD
Fludrocortisone—Methylprednisolone—CYP3A4—bone cancer	0.00338	0.0708	CrCbGaD
Fludrocortisone—Hyperhidrosis—Cisplatin—bone cancer	0.00332	0.00506	CcSEcCtD
Fludrocortisone—Affect lability—Doxorubicin—bone cancer	0.00327	0.00498	CcSEcCtD
Fludrocortisone—Pancreatitis—Methotrexate—bone cancer	0.00325	0.00495	CcSEcCtD
Fludrocortisone—Muscular weakness—Epirubicin—bone cancer	0.00317	0.00482	CcSEcCtD
Fludrocortisone—Mood swings—Doxorubicin—bone cancer	0.00315	0.00479	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00313	0.00476	CcSEcCtD
Fludrocortisone—Abdominal distension—Epirubicin—bone cancer	0.00312	0.00475	CcSEcCtD
Fludrocortisone—Pancreatitis—Epirubicin—bone cancer	0.00304	0.00463	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00303	0.0103	CbGpPWpGaD
Fludrocortisone—Muscular weakness—Doxorubicin—bone cancer	0.00293	0.00446	CcSEcCtD
Fludrocortisone—Abdominal distension—Doxorubicin—bone cancer	0.00289	0.0044	CcSEcCtD
Fludrocortisone—Triamcinolone—CYP3A4—bone cancer	0.00285	0.0597	CrCbGaD
Fludrocortisone—Pancreatitis—Doxorubicin—bone cancer	0.00281	0.00428	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Epirubicin—bone cancer	0.0028	0.00426	CcSEcCtD
Fludrocortisone—Triamcinolone—PTGS2—bone cancer	0.00279	0.0585	CrCbGaD
Fludrocortisone—AR—FOXA1 transcription factor network—JUN—bone cancer	0.00277	0.00936	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.00274	0.00928	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—FUS—bone cancer	0.00272	0.00922	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Methotrexate—bone cancer	0.00267	0.00406	CcSEcCtD
Fludrocortisone—Haemorrhage—Methotrexate—bone cancer	0.00265	0.00404	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00265	0.00896	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.00263	0.00892	CbGpPWpGaD
Fludrocortisone—Hyperglycaemia—Doxorubicin—bone cancer	0.00259	0.00394	CcSEcCtD
Fludrocortisone—AR—Gene Expression—ZNF77—bone cancer	0.00259	0.00876	CbGpPWpGaD
Fludrocortisone—Prednisone—CYP3A4—bone cancer	0.00259	0.0541	CrCbGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00258	0.00873	CbGpPWpGaD
Fludrocortisone—Medroxyprogesterone Acetate—CYP3A4—bone cancer	0.00257	0.0539	CrCbGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00255	0.00862	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Cisplatin—bone cancer	0.00253	0.00385	CcSEcCtD
Fludrocortisone—Haemoglobin—Epirubicin—bone cancer	0.0025	0.0038	CcSEcCtD
Fludrocortisone—Haemorrhage—Epirubicin—bone cancer	0.00248	0.00378	CcSEcCtD
Fludrocortisone—Asthenia—Cisplatin—bone cancer	0.00246	0.00375	CcSEcCtD
Fludrocortisone—Methyltestosterone—CYP3A4—bone cancer	0.00242	0.0507	CrCbGaD
Fludrocortisone—Prednisolone—CYP3A4—bone cancer	0.00238	0.0499	CrCbGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.00238	0.00807	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.00238	0.00804	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00235	0.00795	CbGpPWpGaD
Fludrocortisone—Betamethasone—CYP3A4—bone cancer	0.00234	0.0489	CrCbGaD
Fludrocortisone—Erythema—Methotrexate—bone cancer	0.00231	0.00352	CcSEcCtD
Fludrocortisone—Haemoglobin—Doxorubicin—bone cancer	0.00231	0.00352	CcSEcCtD
Fludrocortisone—Haemorrhage—Doxorubicin—bone cancer	0.0023	0.0035	CcSEcCtD
Fludrocortisone—Betamethasone—PTGS2—bone cancer	0.00229	0.0479	CrCbGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.00222	0.00751	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00221	0.00747	CbGpPWpGaD
Fludrocortisone—Erythema—Epirubicin—bone cancer	0.00216	0.00329	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00216	0.0073	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00214	0.00724	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.00212	0.00719	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00211	0.00714	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.00208	0.00704	CbGpPWpGaD
Fludrocortisone—Vertigo—Methotrexate—bone cancer	0.00207	0.00316	CcSEcCtD
Fludrocortisone—Convulsion—Methotrexate—bone cancer	0.002	0.00305	CcSEcCtD
Fludrocortisone—Erythema—Doxorubicin—bone cancer	0.002	0.00304	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.002	0.00676	CbGpPWpGaD
Fludrocortisone—Myalgia—Methotrexate—bone cancer	0.00197	0.00299	CcSEcCtD
Fludrocortisone—NR3C1—Gene Expression—ZNF77—bone cancer	0.00196	0.00664	CbGpPWpGaD
Fludrocortisone—Vertigo—Epirubicin—bone cancer	0.00194	0.00296	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—NR1I2—bone cancer	0.00189	0.00639	CbGpPWpGaD
Fludrocortisone—Anaphylactic shock—Methotrexate—bone cancer	0.00188	0.00287	CcSEcCtD
Fludrocortisone—Convulsion—Epirubicin—bone cancer	0.00187	0.00285	CcSEcCtD
Fludrocortisone—Infection—Methotrexate—bone cancer	0.00187	0.00285	CcSEcCtD
Fludrocortisone—Hypertension—Epirubicin—bone cancer	0.00187	0.00284	CcSEcCtD
Fludrocortisone—Myalgia—Epirubicin—bone cancer	0.00184	0.0028	CcSEcCtD
Fludrocortisone—Hydrocortisone—CYP3A4—bone cancer	0.00182	0.0382	CrCbGaD
Fludrocortisone—Hyperhidrosis—Methotrexate—bone cancer	0.00182	0.00277	CcSEcCtD
Fludrocortisone—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.00182	0.00616	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.00181	0.00613	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.00181	0.00612	CbGpPWpGaD
Fludrocortisone—Vertigo—Doxorubicin—bone cancer	0.0018	0.00274	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00179	0.00605	CbGpPWpGaD
Fludrocortisone—Oedema—Epirubicin—bone cancer	0.00176	0.00269	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Epirubicin—bone cancer	0.00176	0.00269	CcSEcCtD
Fludrocortisone—Infection—Epirubicin—bone cancer	0.00175	0.00267	CcSEcCtD
Fludrocortisone—Convulsion—Doxorubicin—bone cancer	0.00173	0.00264	CcSEcCtD
Fludrocortisone—Hypertension—Doxorubicin—bone cancer	0.00173	0.00263	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00172	0.00261	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.00171	0.0058	CbGpPWpGaD
Fludrocortisone—Hyperhidrosis—Epirubicin—bone cancer	0.00171	0.0026	CcSEcCtD
Fludrocortisone—Insomnia—Methotrexate—bone cancer	0.0017	0.0026	CcSEcCtD
Fludrocortisone—Myalgia—Doxorubicin—bone cancer	0.0017	0.00259	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.0017	0.00575	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.00167	0.00565	CbGpPWpGaD
Fludrocortisone—Anaphylactic shock—Doxorubicin—bone cancer	0.00163	0.00248	CcSEcCtD
Fludrocortisone—Oedema—Doxorubicin—bone cancer	0.00163	0.00248	CcSEcCtD
Fludrocortisone—Infection—Doxorubicin—bone cancer	0.00162	0.00247	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00161	0.00245	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.0016	0.00542	CbGpPWpGaD
Fludrocortisone—Insomnia—Epirubicin—bone cancer	0.0016	0.00243	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Doxorubicin—bone cancer	0.00158	0.0024	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.00157	0.00533	CbGpPWpGaD
Fludrocortisone—Urticaria—Methotrexate—bone cancer	0.0015	0.00228	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00149	0.00226	CcSEcCtD
Fludrocortisone—Progesterone—CYP3A4—bone cancer	0.00149	0.0311	CrCbGaD
Fludrocortisone—Insomnia—Doxorubicin—bone cancer	0.00148	0.00225	CcSEcCtD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.00147	0.00497	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—JUN—bone cancer	0.00145	0.0049	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00142	0.00479	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	0.00141	0.00477	CbGpPWpGaD
Fludrocortisone—Testosterone—CYP3A4—bone cancer	0.0014	0.0294	CrCbGaD
Fludrocortisone—Urticaria—Epirubicin—bone cancer	0.0014	0.00213	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—EIF2S1—bone cancer	0.00139	0.00472	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.00139	0.00471	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Methotrexate—bone cancer	0.00139	0.00211	CcSEcCtD
Fludrocortisone—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	0.00138	0.00467	CbGpPWpGaD
Fludrocortisone—Dexamethasone—CYP3A4—bone cancer	0.00136	0.0284	CrCbGaD
Fludrocortisone—Asthenia—Methotrexate—bone cancer	0.00135	0.00206	CcSEcCtD
Fludrocortisone—Dexamethasone—PTGS2—bone cancer	0.00133	0.0278	CrCbGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00133	0.00449	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Epirubicin—bone cancer	0.0013	0.00198	CcSEcCtD
Fludrocortisone—Urticaria—Doxorubicin—bone cancer	0.0013	0.00197	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.00129	0.00436	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	0.00128	0.00432	CbGpPWpGaD
Fludrocortisone—Asthenia—Epirubicin—bone cancer	0.00127	0.00193	CcSEcCtD
Fludrocortisone—AR—Gene Expression—FUS—bone cancer	0.00126	0.00428	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.00124	0.00419	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—EZH2—bone cancer	0.00121	0.0041	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Doxorubicin—bone cancer	0.0012	0.00183	CcSEcCtD
Fludrocortisone—NR3C1—Adipogenesis—RB1—bone cancer	0.00119	0.00403	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00119	0.00402	CbGpPWpGaD
Fludrocortisone—Headache—Methotrexate—bone cancer	0.00118	0.0018	CcSEcCtD
Fludrocortisone—Asthenia—Doxorubicin—bone cancer	0.00117	0.00178	CcSEcCtD
Fludrocortisone—Headache—Epirubicin—bone cancer	0.0011	0.00168	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00103	0.00349	CbGpPWpGaD
Fludrocortisone—Headache—Doxorubicin—bone cancer	0.00102	0.00156	CcSEcCtD
Fludrocortisone—AR—SIDS Susceptibility Pathways—JUN—bone cancer	0.001	0.0034	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000983	0.00333	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—FUS—bone cancer	0.000959	0.00324	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—TP53—bone cancer	0.000955	0.00323	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000948	0.00321	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—NR1I2—bone cancer	0.000876	0.00296	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000855	0.00289	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000842	0.00285	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000811	0.00274	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000762	0.00258	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000681	0.0023	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000672	0.00227	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—NR1I2—bone cancer	0.000664	0.00225	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—EIF2S1—bone cancer	0.000647	0.00219	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000564	0.00191	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—EZH2—bone cancer	0.000562	0.0019	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—EIF2S1—bone cancer	0.000491	0.00166	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—EZH2—bone cancer	0.000426	0.00144	CbGpPWpGaD
